Anti-TNF alpha medications and neuropathy

Journal of the Peripheral Nervous System

Volumn 20, Issue 4, 2015, Pages 397-402

  Tsouni, Pinelopi ^a   Bill, Olivier ^a   Truffert, André ^b   Liaudat, Christelle ^a   Ochsner, François ^a   Steck, Andreas J ^a,c   Kuntzer, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

anti TNF alpha; demyelination; inflammation; neuropathies

Indexed keywords

ADALIMUMAB; CAPSAICIN; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; AREFLEXIA; ARM WEAKNESS; ARTICLE; ATAXIC GAIT; BURNING SENSATION; CARPAL TUNNEL SYNDROME; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CROHN DISEASE; DEMYELINATION; DRUG WITHDRAWAL; DYSESTHESIA; ELECTROMYOGRAPHY; ERYTHROMELALGIA; FEMALE; FEMORAL NEUROPATHY; GAIT DISORDER; HUMAN; HYPOREFLEXIA; INFLAMMATORY DISEASE; INGUINAL PAIN; LOW BACK PAIN; MALE; MOTOR NEUROPATHY; MUSCLE WEAKNESS; NERVE CONDUCTION; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PERONEAL NEUROPATHY; PERONEUS NERVE PARALYSIS; POLYRADICULONEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUADRIPLEGIA; RADICULITIS; RADICULOPATHY; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SMALL FIBER NEUROPATHY; ULCERATIVE COLITIS; WALKING DIFFICULTY; WEAKNESS; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CHEMICALLY INDUCED; ELECTRODIAGNOSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY; RHEUMATIC DISEASES;

ADALIMUMAB; ADULT; AGED; AUTOIMMUNE DISEASES; ELECTRODIAGNOSIS; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959499338     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12147     Document Type: Article

References (18)

1. Alshekhlee A, Basiri K, Miles JD, Ahmad SA, Katirji B, (2010). Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve 41: 723-727.
2. Anonymous (1999). TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53: 457-465.
3. Bill O, Tsouni P, Benninger DH, Renard D, Truffert A, Ochsner F, Buclin T, Kuntzer T, (2013). Immunomodulatory or immunosuppressive-induced neuropathies. J Peripher Nerv Syst 18: S13.
4. EFNS/PNS (2010). European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - First Revision. J Peripher Nerv Syst 15: 1-9.
5. Gondim FA, Brannagan TH 3rd, Sander HW, Chin RL, Latov N, (2005). Peripheral neuropathy in patients with inflammatory bowel disease. Brain 128: 867-879.
6. Gupta G, Gelfand JM, Lewis JD, (2005). Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129: 819-826.
7. Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA, (2014). Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther 16: R125.
8. Lozeron P, Denier C, Lacroix C, Adams D, (2009). Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66: 490-497.
9. Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL, Daniel R, Judson MA, (2011). Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci 342: 352-355.
10. Ramos-Remus C, Duran-Barragan S, Castillo-Ortiz JD, (2012). Beyond the joints: neurological involvement in rheumatoid arthritis. Clin Rheumatol 31: 1-12.
11. Renard D, Gauthier T, Venetz JP, Buclin T, Kuntzer T, (2012). Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. Clin Kidney J 5: 323-326.
12. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J, (2005). Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 64: 1468-1470.
13. Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, Houvenagel E, Berthelot JM, Pagnoux C, Dernis E, Melac-Ducamp S, Bouvard B, Asquier C, Martin A, Puechal X, Mariette X, Club Rhumatismes et Inflammation Section of the SFR (2013). Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey. Rheumatology 52: 868-874.
14. Singh S, Kumar N, Loftus EV Jr, Kane SV, (2013). Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis 19: 864-872.
15. Stovicek J, Liskova P, Lisy J, Hlava S, Keil R, (2014). Crohn's disease: is there a place for neurological screening? Scand J Gastroenterol 49: 173-176.
16. Stubgen JP, (2008). Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37: 281-292.
17. Theibich A, Dreyer L, Magyari M, Locht H, (2014). Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Clin Rheumatol 33: 719-723.
18. Tristano AG, (2010). Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 257: 1421-1431.